SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Applied Materials, Inc. engages in provision of materials engineering solutions used to produce semiconductors. The firm also focuses on design, development, production, and servicing of the critical wafer fabrication tools used for customers to manufacture semiconductors. It operates through the following segments: Semiconductor Systems and Applied Global Services (AGS). The Semiconductor Systems segment includes designing, development, manufacturing and sale of equipment used to fabricate semiconductor chips referred to as integrated circuits. The AGS segment engages in provision of services, spares, and factory automation software to customer fabrication plants globally. The company was founded on November 10, 1967 and is headquartered in Santa Clara, CA.

Applied Materials Inc.

Applied Materials is facing intense scrutiny as investors debate whether current semiconductor demand and AI-driven growth justify recent valuation shifts. While some community members highlight strong fundamental outlooks and long-term infrastructure potential, others are actively tracking short positions and market volatility as potential signs of an overextended sector.

TSS, Inc. engages in the provision of comprehensive services for the planning, design, development and maintenance of mission-critical facilities and information infrastructure as well as integration services. It operates through the Facilities and Systems Integration Services business segments. The Facilities segment consists of the design, project management, and maintenance of data center and mission-critical business operations. The Systems Integration segment integrates information technology equipment for original equipment manufacturer vendors and customers to be used inside data center environments, including modular data centers. The company was founded by Gerard J. Gallagher on December 20, 2004 and is headquartered in Georgetown, TX.

TSS Inc

TSS Inc. is facing intense community scrutiny and downward price pressure following a weak earnings report that showed significant revenue decline, fueling investor frustration over the company's heavy reliance on Dell and its inability to capitalize on the AI infrastructure boom. While some bulls argue the pivot toward higher-margin systems integration represents a long-term strategic transformation, critics are dismissing the stock as a 'value trap' due to persistent execution concerns and lack of growth.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is trending as investors focus on the company's clear path to a Q4 BLA submission for its prostate cancer therapy, bolstered by successful FDA alignment on manufacturing and comparability. Community sentiment remains bullish, with ongoing discussions centered on high institutional ownership and the potential for a massive addressable market.

QXO, Inc. is a publicly traded distributor of roofing, waterproofing and complementary building products in the United States. It plans to become tech-enabled in the building products distribution industry and generate outsized value for shareholders. The company was founded on October 3, 2002, and is headquartered in Greenwich, CT.

QXO Inc.

QXO is trending as investors digest the impact of recent acquisitions, with the community actively debating whether the company's long-term turnaround strategy justifies its current price action amid lack of formal earnings calls. While some participants are wary of dilution and poor sentiment, others view the stock as a deeply undervalued, long-term opportunity driven by strong institutional backing and a seasoned leadership team.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is rallying as investors turn bullish on its strategic pivot into agentic AI orchestration and software sector recovery, with the community closely tracking high short interest as a potential catalyst for a sustained squeeze. The stock's recent price appreciation, fueled by institutional accumulation and improved fundamentals, has shifted sentiment from bearish skepticism to optimism for long-term growth as market participants look ahead to upcoming earnings.

Nu Holdings Ltd. is a holding company, which engages in the provision of digital banking services. The company was founded by David Vélez Osorno, Cristina Helena Zingaretti Junqueira, and Adam Edward Wible on February 26, 2016 and is headquartered in São Paulo, Brazil.

Nu Holdings Ltd - Ordinary Shares Class A

Nu Holdings Ltd

Nu Holdings is facing downward pressure amid investor uncertainty following the announcement of a leadership transition in the CFO role and a subsequent analyst downgrade, despite the company's strong recent earnings and newly authorized share repurchase program. The community remains divided between those viewing the price dip as a strategic long-term buying opportunity given the firm's rapid expansion and fintech dominance, and those frustrated by the stock's persistent lack of upward momentum.

Workday, Inc. engages in the development of enterprise cloud applications for finance and human resources. The firm delivers financial management, human capital management and analytics applications designed for companies, educational institutions, and government agencies. It operates through the Cloud Applications segment. The company was founded by David A. Duffield and Aneel Bhusri in 2005 and is headquartered in Pleasanton, CA.

Workday Inc - Ordinary Shares - Class A

Workday Inc

Workday stock is seeing a massive surge as investors react to reports that private equity giant Silver Lake is exploring a potential acquisition of the company. The community is actively debating the credibility and valuation of these buyout rumors, with many traders questioning the likelihood of a deal while others highlight the resulting upward pressure on the broader software sector.

Fundrise Innovation Fund LLC operates as a non-diversified, closed-end management investment company. It invests in growing tech companies to help them expand and generate profits. The company was founded on June 7, 2021 and is headquartered in Washington, DC.

Fundrise Innovation Fund LLC. - Common Shares of Limited Liability Company Interests

Fundrise Innovation Fund 

VCX is experiencing significant volatility driven by the upcoming August 14 lockup expiration, which has sparked intense debate among the community regarding its fair value versus its current premium to NAV. Investors are closely monitoring the fund's heavy exposure to private AI and aerospace giants like Anthropic and SpaceX, leading to active discussions about whether the current price represents a long-term accumulation opportunity or a continuing 'pump and dump' correction.

York Space Systems, Inc. engages in providing a comprehensive suite of mission-critical solutions for national security, government, and commercial customers. It offers a vertically integrated, full technology stack of solutions including design, production, integration, and operation of spacecraft with turnkey offerings to manage spacecraft and constellations throughout the entire mission lifecycle. The company was founded by Dirk Wallinger in January 2012 and is headquartered in Denver, CO.

York Space Systems Inc

York Space Systems is facing intense pressure following a lower full-year revenue outlook attributed to shifting procurement processes, prompting investors to pivot toward short-term speculation amid concerns over leadership stability and insider selling. While some community members view the dip as an opportunistic entry point based on long-term backlog potential, others remain skeptical, citing continued profitability struggles and negative sentiment following recent third-party research reports.

ARS Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development of a novel, potentially first-in-class product candidate, neffy, for the emergency treatment of Type I allergic reactions including anaphylaxis. Its product includes Epinephrine Nasal Spray. The company was founded by Richard Lowenthal, Robert Bell, and Sarina Tanimoto on August 5, 2015 and is headquartered in San Diego, CA.

ARS Pharmaceuticals Inc

SPRY is trending as investors weigh its role as a first-mover in the needle-free epinephrine market against ongoing concerns about cash burn, high short interest, and competitive pressures from potential alternatives like AQST. While some community members highlight the stock's long-term commercial upside and institutional backing, others are aggressively betting against it, citing lack of formulary wins and the company's heavy reliance on a single product.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Aethlon Medical Reports Q1 Fiscal 2027 Results and Progress on Hemopurifier Program

Aethlon Medical Reports Q1 Fiscal 2027 Results and Progress on Hemopurifier Program Aethlon Medical Reports Q1 Fiscal 2027 Results and Progress on Hemopurifier Program PR Newswire SAN DIEGO, Aug. 13, 2026 Conference Call Today at 4:30 p.m. ETSAN DIEGO, Aug. 13, 2026 /PRNewswire/ -- Aethlon Medical...

Aethlon Medical to Release First Quarter Financial Results and Host Conference Call on August 13, 2026

Aethlon Medical to Release First Quarter Financial Results and Host Conference Call on August 13, 2026 Aethlon Medical to Release First Quarter Financial Results and Host Conference Call on August 13, 2026 PR Newswire SAN DIEGO, Aug. 5, 2026 SAN DIEGO, Aug. 5, 2026 /PRNewswire/ -- Aethlon Medical...

Aethlon Medical Continues to Observe Directional Changes in Second Cohort of Australian Oncology Clinical Trial Evaluating Hemopurifier

Aethlon Medical Continues to Observe Directional Changes in Second Cohort of Australian Oncology Clinical Trial Evaluating Hemopurifier Aethlon Medical Continues to Observe Directional Changes in Second Cohort of Australian Oncology Clinical Trial Evaluating Hemopurifier PR Newswire SAN DIEGO, July...

Aethlon Medical Announces Pricing of $4.0 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules

Aethlon Medical Announces Pricing of $4.0 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules Aethlon Medical Announces Pricing of $4.0 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules PR Newswire SAN DIEGO, July 6, 2026 SAN DIEGO, July 6, 2026 /PRNewswire...

Aethlon Medical Announces Publication Demonstrating Novel Long COVID Biomarker and Potential Therapeutic Target for the Hemopurifier

Aethlon Medical Announces Publication Demonstrating Novel Long COVID Biomarker and Potential Therapeutic Target for the Hemopurifier Aethlon Medical Announces Publication Demonstrating Novel Long COVID Biomarker and Potential Therapeutic Target for the Hemopurifier PR Newswire SAN DIEGO, June 26...

Aethlon Medical Announces Fiscal Year End March 31, 2026 Financial Results and Corporate Update

Aethlon Medical Announces Fiscal Year End March 31, 2026 Financial Results and Corporate Update Aethlon Medical Announces Fiscal Year End March 31, 2026 Financial Results and Corporate Update PR Newswire SAN DIEGO, June 10, 2026 Australian oncology study advances into Cohort 3 as enrollment...

The Next Meme Stock Wave?

A fresh wave of speculative activity swept through the small-cap market this week as traders piled into a combination of AI-linked companies, China-based growth stories, and emerging defense contractors. $BLIS, $GMM, $PAVS, $AEMD, $PAYO, $AZI, $CGTL, $CCSC, $ELPW, $JZXN, $MTEN

Aethlon Medical to Release Fiscal Year End Financial Results and Host Conference Call on June 10, 2026

Aethlon Medical to Release Fiscal Year End Financial Results and Host Conference Call on June 10, 2026 Aethlon Medical to Release Fiscal Year End Financial Results and Host Conference Call on June 10, 2026 PR Newswire SAN DIEGO, June 2, 2026 SAN DIEGO, June 2, 2026 /PRNewswire/ --Aethlon Medical...

Aethlon Medical Monitoring Current Ebola Outbreak and Reaffirms Outbreak/Pandemic Preparedness

Aethlon Medical Monitoring Current Ebola Outbreak and Reaffirms Outbreak/Pandemic Preparedness Aethlon Medical Monitoring Current Ebola Outbreak and Reaffirms Outbreak/Pandemic Preparedness PR Newswire SAN DIEGO, May 21, 2026 SAN DIEGO, May 21, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ...

Aethlon Medical, Inc. Advances to Final Cohort in Oncology Clinical Trial Following Positive DSMB Review

Aethlon Medical, Inc. Advances to Final Cohort in Oncology Clinical Trial Following Positive DSMB Review Aethlon Medical, Inc. Advances to Final Cohort in Oncology Clinical Trial Following Positive...

Aethlon Medical, Inc. is a medical technology company which focuses on developing products to diagnose and treat life and organ threatening diseases. It develops Aethlon Hemopurifier, which is a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening viral infections. The firm operates through the following segments: Aethlon and ESI. The Aethlon segment is involved in therapeutic business activities. The ESI segment consists of diagnostic business activities. The company was founded by James A. Joyce on April 17, 1991 and is headquartered in San Diego, CA.

Aethlon Medical Inc

Why Did Aethlon Medical Stock Tumble Over 12% Today?

Equity

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

AEMDAethlon Medical Inc

Fundamentals

Connect Stocktwits to ChatGPT

Latest AEMD News